0001144204-18-064668.txt : 20181214
0001144204-18-064668.hdr.sgml : 20181214
20181214163031
ACCESSION NUMBER: 0001144204-18-064668
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181212
FILED AS OF DATE: 20181214
DATE AS OF CHANGE: 20181214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COOPER GRAHAM K
CENTRAL INDEX KEY: 0001396943
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35005
FILM NUMBER: 181235923
MAIL ADDRESS:
STREET 1: C/O RECEPTOS, INC.
STREET 2: 10835 ROAD TO THE CURE, SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001426800
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11711 N. MERIDIAN STREET
STREET 2: SUITE 310
CITY: CARMEL
STATE: IN
ZIP: 46032
BUSINESS PHONE: (212) 554-4388
MAIL ADDRESS:
STREET 1: 11711 N. MERIDIAN STREET
STREET 2: SUITE 310
CITY: CARMEL
STATE: IN
ZIP: 46032
FORMER COMPANY:
FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC
DATE OF NAME CHANGE: 20080211
4
1
tv509183_form4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-12-12
0
0001426800
ASSEMBLY BIOSCIENCES, INC.
ASMB
0001396943
COOPER GRAHAM K
C/O ASSEMBLY BIOSCIENCES, INC.
11711 N. MERIDIAN STREET, SUITE 310
CARMEL
IN
46032
0
1
0
0
See Remarks
Common Stock
2018-12-12
4
A
0
100000
0
A
100000
D
Represents shares of common stock issuable under a time-based restricted stock unit ("RSU") award dated December 12, 2018 that was granted under Assembly Biosciences, Inc.'s 2018 Stock Incentive Plan. Assuming continuous service through each vesting date, 50,000 RSUs vest in the following installments: 20,000 RSUs vest on December 12, 2019 and 10,000 RSUs vest on each of June 12, 2020, December 12, 2020 and June 12, 2021. The remaining 50,000 RSUs vest on June 12, 2021, subject to accelerated vesting upon achievement of certain performance milestones, but in no event will such RSUs vest as a result of such performance milestones prior to December 12, 2019.
Chief Financial Officer and Chief Operating Officer
/s/ Elizabeth H. Lacy, as Attorney-in-Fact
2018-12-14